These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 33787270)
41. A clinical update of using albumin as a drug vehicle - a commentary. Kratz F J Control Release; 2014 Sep; 190():331-6. PubMed ID: 24637463 [TBL] [Abstract][Full Text] [Related]
42. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM). Madaan A; Singh P; Awasthi A; Verma R; Singh AT; Jaggi M; Mishra SK; Kulkarni S; Kulkarni H Clin Transl Oncol; 2013 Jan; 15(1):26-32. PubMed ID: 22855169 [TBL] [Abstract][Full Text] [Related]
43. Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. Zhang F; Zhang S; Pollack SF; Li R; Gonzalez AM; Fan J; Zou J; Leininger SE; Pavía-Sanders A; Johnson R; Nelson LD; Raymond JE; Elsabahy M; Hughes DM; Lenox MW; Gustafson TP; Wooley KL J Am Chem Soc; 2015 Feb; 137(5):2056-66. PubMed ID: 25629952 [TBL] [Abstract][Full Text] [Related]
44. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Zhao D; Zhao X; Zu Y; Li J; Zhang Y; Jiang R; Zhang Z Int J Nanomedicine; 2010 Sep; 5():669-77. PubMed ID: 20957218 [TBL] [Abstract][Full Text] [Related]
45. Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Baek JS; Kim JH; Park JS; Cho CW Int J Nanomedicine; 2015; 10():5397-405. PubMed ID: 26347363 [TBL] [Abstract][Full Text] [Related]
46. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. Van de Sande L; Cosyns S; Willaert W; Ceelen W Drug Deliv; 2020 Dec; 27(1):40-53. PubMed ID: 31858848 [TBL] [Abstract][Full Text] [Related]
48. Bioactive albumin-based carriers for tumour chemotherapy. Shahzad Y; Khan IU; Hussain T; Alamgeer ; Serra CA; Rizvi SA; Gerber M; du Plessis J Curr Cancer Drug Targets; 2014; 14(8):752-63. PubMed ID: 25348019 [TBL] [Abstract][Full Text] [Related]
49. Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors. Yang Y; Bteich J; Li SD AAPS J; 2017 Mar; 19(2):386-396. PubMed ID: 27873118 [TBL] [Abstract][Full Text] [Related]
50. Donor-Acceptor-Type Conjugated Polymer-Based Multicolored Drug Carriers with Tunable Aggregation-Induced Emission Behavior for Self-Illuminating Cancer Therapy. Wang Z; Wang C; Gan Q; Cao Y; Yuan H; Hua D ACS Appl Mater Interfaces; 2019 Nov; 11(45):41853-41861. PubMed ID: 31668068 [TBL] [Abstract][Full Text] [Related]
51. Drug Delivery Vehicles Based on Albumin-Polymer Conjugates. Jiang Y; Stenzel M Macromol Biosci; 2016 Jun; 16(6):791-802. PubMed ID: 26947019 [TBL] [Abstract][Full Text] [Related]
52. An optimized two-vial formulation lipid nanoemulsion of paclitaxel for targeted delivery to tumor. Chen L; Chen B; Deng L; Gao B; Zhang Y; Wu C; Yu N; Zhou Q; Yao J; Chen J Int J Pharm; 2017 Dec; 534(1-2):308-315. PubMed ID: 28986321 [TBL] [Abstract][Full Text] [Related]
53. Amphiphilic cyclodextrin nanoparticles for effective and safe delivery of anticancer drugs. Bilensoy E Adv Exp Med Biol; 2015; 822():201. PubMed ID: 25416992 [No Abstract] [Full Text] [Related]
54. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. Kim JH; Kim Y; Bae KH; Park TG; Lee JH; Park K Mol Pharm; 2015 Apr; 12(4):1230-41. PubMed ID: 25686010 [TBL] [Abstract][Full Text] [Related]
55. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Gawde KA; Sau S; Tatiparti K; Kashaw SK; Mehrmohammadi M; Azmi AS; Iyer AK Colloids Surf B Biointerfaces; 2018 Jul; 167():8-19. PubMed ID: 29625422 [TBL] [Abstract][Full Text] [Related]
56. Conjugation of paclitaxel to iron oxide nanoparticles for tumor imaging and therapy. Liu D; Wu W; Chen X; Wen S; Zhang X; Ding Q; Teng G; Gu N Nanoscale; 2012 Apr; 4(7):2306-10. PubMed ID: 22362270 [TBL] [Abstract][Full Text] [Related]
57. Albumin-based nanoparticles as potential controlled release drug delivery systems. Elzoghby AO; Samy WM; Elgindy NA J Control Release; 2012 Jan; 157(2):168-82. PubMed ID: 21839127 [TBL] [Abstract][Full Text] [Related]
58. Metabolism of the taxanes including nab-paclitaxel. Joerger M Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848 [TBL] [Abstract][Full Text] [Related]
59. Role of Albumin as a Targeted Drug Carrier in the Management of Rheumatoid Arthritis: A Comprehensive Review. Garg U; Jain N; Kaul S; Nagaich U Mol Pharm; 2023 Nov; 20(11):5345-5358. PubMed ID: 37870420 [TBL] [Abstract][Full Text] [Related]
60. Harnessing albumin as a carrier for cancer therapies. Hoogenboezem EN; Duvall CL Adv Drug Deliv Rev; 2018 May; 130():73-89. PubMed ID: 30012492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]